Is ARTV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ARTV. It does not provide personalized investment advice.

ARTV (Artiva Biotherapeutics, Inc. Common Stock) Stock Analysis - Financials

Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a publicly traded Healthcare sector company. As of July 15, 2026, ARTV trades at $9.67 with a market cap of $433.89M and a P/E ratio of -2.72. ARTV moved +4.82% today. Year to date, ARTV is +117.95%; over the trailing twelve months it is +328.90%. Its 52-week range spans $1.47 to $14.53. Analyst consensus is strong buy with an average price target of $35.80. Rallies surfaces ARTV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are ARTV's key financials?

ARTV financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ARTV recently traded at $9.67. Market cap is $433.89M. P/E ratio is -2.72. Revenue is $0.

ARTV Key Metrics

Key financial metrics for ARTV
Metric	Value
Price	$9.67
Market Cap	$433.89M
P/E Ratio	-2.72
EPS	$-3.43
Dividend Yield	0.00%
52-Week High	$14.53
52-Week Low	$1.47
Volume	385.74K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-83.86M
Gross Margin	0.00%

ARTV Analyst Consensus

6 analysts cover ARTV: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.80.

Common questions about ARTV

What are ARTV's key financials?: ARTV financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ARTV recently traded at $9.67. Market cap is $433.89M. P/E ratio is -2.72. Revenue is $0.
Is ARTV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ARTV. It does not provide personalized investment advice.